Brokerage Reports
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 301 - 310 ( 310 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Q3:10 Earnings a Non-Event, Focus Remains on Full ALS Data in December
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Price: 10.00
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Price: 10.00
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Price: 10.00
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Reports Q2:10 Earnings and Provides Update to CK-?357 and omecamtiv mecarbil Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Price: 10.00
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Price: 10.00
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Initiates CK-?357 Peripheral Artery Disease and Claudication Phase IIa Study
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Price: 25.00
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Price: 10.00
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Q1:10 Earnings and Update to CK-?357 Studies and omecamtiv mecarbil Studies
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Price: 10.00
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
CYTK Announces Statistically Significant Results from the CK-20173537 Phase I Trial
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Price: 10.00